Using various genetically engineered mouse models, we found that tumor‐derived RECQL4 inhibited cGAS‐STING pathway activation in dendritic cells and anti‐tumor immune reorganization after RT, thereby reducing the sensitivity to HCC treatment. Here, RECQL4 is linked to neoplasm.